Dr Tirziu Dermato-Chirurgie S.R.L.
- Address
- Strada Mangalia No 31a, 300188 Timișoara, Romania
Immune System Diseases Research
At Dr Tirziu Dermato-Chirurgie S.R.L. in Timisoara, the clinical trial portfolio focuses on immune system diseases, with research centered on chronic inflammatory skin conditions. The main diseases being studied are hidradenitis suppurativa and atopic dermatitis, reflecting a strong interest in improving care for patients with difficult-to-manage dermatologic disease.
- Evaluating new treatment options for hidradenitis suppurativa
- Assessing therapy effectiveness in atopic dermatitis
- Studying approaches that may improve symptom control and patient outcomes
These trials are designed to better understand how emerging therapies perform in real patients, with attention to both effectiveness and safety.
Inflammatory Skin Disease Trials
The site's research activity also highlights clinical studies in dermatology related to persistent inflammatory skin disorders. One focus is hidradenitis suppurativa, where trials are testing whether a new therapy can reduce disease activity, while another examines atopic dermatitis in adults who have not responded adequately to prior treatment.
- Testing a new therapy for hidradenitis suppurativa
- Comparing treatment options for atopic dermatitis
- Improving understanding of treatment response in difficult cases
Overall, the research at this Romanian site is aimed at finding better ways to manage chronic skin inflammation and support patients who need more effective options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dr Tirziu Dermato-Chirurgie S.R.L.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects with Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP) | AbbVie Deutschland GmbH & Co. KG | Phase I | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Clindamycin Hydrochloride | 1 | Unknown | 2025-06-13 | 2025-06-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.